CTI Biopharma reported $19.92M in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Baxter International BAX:US USD 1.47B 322M
Bristol Myers Squibb BMY:US USD 8.89B 21M
CTI Biopharma CTIC:US USD 19.92M 2.83M
Eli Lilly And LLY:US USD 5.75B 391.2M
Novartis NOVN:VX USD 9.16B 21M
Novartis NVS:US USD 9.16B 21M
Seattle Genetics SGEN:US USD 419.94M 17.76M
Teva Pharmaceutical Industries TEVA:US USD 2.1B 390M
YTE INCY:US USD 872.94M 98.92M